Observed versus expected morbidity and mortality in patients undergoing mitral valve repair.

ABSTRACT:

Objectives

Mitral valve repair (MVP) is the gold standard treatment for degenerative mitral regurgitation. With the expansion of transcatheter technologies, this study compares the outcome of MVP in low-risk and non-low-risk patients to serve as a benchmark.

Methods

This retrospective, single-institution study examined all patients who underwent MVP for primary mitral regurgitation from 2005 to 2018. Patients were stratified into 2 risk categories: low-risk [Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (STS-PROM) ≤2%] and non-low risk (STS-PROM > 2% or age > 75), with a subgroup of very low risk (STS-PROM ≤1%, age <75).

Results

A total of 1207 patients were included, and 1053 patients were classified as low risk and 154 as non-low risk. The non-low-r

SUBMITTER: Newell P 

PROVIDER: S-EPMC9553224 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature